| Page 8 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Author(s): 
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T
Primary Author: 
Platzbecker U
Journal Title: 
Lancet
Original Publication Date: 
Jul 2023

Background: Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk

Bone Marrow Disease(s): 

Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia

Author(s): 
Zhao J, Ma L, Zheng M, Su L, Guo X
Primary Author: 
Zhao J
Journal Title: 
Annals of Hematology
Original Publication Date: 
Jul 2023

This meta-analysis was to evaluate the outcome of haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) for

Bone Marrow Disease(s): 

TERC haploid cell reprogramming: a novel therapeutic strategy for aplastic anemia

Author(s): 
Tang X, Xu R, Wang Y, Chen K, Cui S
Primary Author: 
Tang X
Journal Title: 
Molecular Medicine
Original Publication Date: 
Jun 2023

he telomerase RNA component (TERC) gene plays an important role in telomerase-dependent extension and maintenance of the telomeres. In the event of TERC haploinsufficiency,

Bone Marrow Disease(s): 

Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study

Author(s): 
Liu H, Xia L, Weng J, Zhang F, He C, Gao S, Jia J, Chang AC, Lundberg P, Shi J, Sima CS, Sostelly A, Sreckovic S, Xiao Z, Zhang Z, Fu R.
Primary Author: 
Liu H
Journal Title: 
American Journal of Hematology
Original Publication Date: 
Jul 2023

The Phase 3 single-arm COMMODORE 3 study (ClinicalTrials.gov, NCT04654468) evaluated efficacy and safety of crovalimab (novel C5 inhibitor) in complement inhibitor-naive patients with

Bone Marrow Disease(s): 

2023 Salt Lake City Patient and Family Conference

Thank you for attending the 2023 Salt Lake City Patient and Family Conference. We will keep uploading presentations as we receive them, please keep checking back for updates.

Presentation Materials:

Predisposition to Inherited Bone Marrow Failure Syndromes

Event Date: 
Sat, 07/15/2023 - 8:00am (EDT)
Conference Materials: 
File Predisposition to Bone Marrow Failure Syndromes
File P-N-H and Non-Transplant Therapies
File M-D-S and Non-Transplant Therapies
File Aplastic Anemia and Transplant SLC.pptx
File Transplant for M-D-S
Bone Marrow Disease(s): 
Conference Event Type: 
Patient and Family - Regional One Day

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Author(s): 
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T
Primary Author: 
Platzbecker U
Journal Title: 
Lancet
Original Publication Date: 
Jun 2023

Background: Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk

Bone Marrow Disease(s): 

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Author(s): 
Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisà E, Capodanno I, Salutari P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Iannì G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P
Primary Author: 
Oliva EN
Journal Title: 
Journal of Clinical Oncology
Original Publication Date: 
Jun 2023

Purpose: In

Bone Marrow Disease(s): 

Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study

Author(s): 
Stojkov I, Conrads-Frank A, Rochau U, Arvandi M, Koinig KA, Schomaker M, Mittelman M, Fenaux P, Bowen D, Sanz GF, Malcovati L, Langemeijer S, Germing U, Madry K, Guerci-Bresler A, Culligan DJ, Kotsianidis I, Sanhes L, Mills J, Puntscher S, Schmid D
Primary Author: 
Stojkov I
Journal Title: 
Blood Advances
Original Publication Date: 
Jun 2023

Patients with

Bone Marrow Disease(s):